Paper12372721
Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
Schwartz JD and 3 others. Lancet Oncol, 2002. Cited by 220 papers, by iCite.
Cite this record
ConductScience Library. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Papers, record 12372721. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12372721
- Disease
- hepatocellular carcinoma478 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Chemoembolization, Therapeutic | |
| Chemotherapy, Adjuvant | |
| Humans | |
| Radiotherapy, Adjuvant | |
| Randomized Controlled Trials as Topic | |
| Research Design | |
| Survival Analysis |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06041477 | Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | Results |
Source ClinicalTrials.gov
Cited by90
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 220 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41935630 | IMAT-HCC model: Liver stiffness-enhanced integrated risk stratification for HCC recurrence after resection. | JHEP Rep | 2026 | https://conductscience.org/library/papers/41935630 | PubMed |
| 41024879 | Postoperative adjuvant management in hepatocellular carcinoma: A review of therapeutic efficacy and prognostic outcomes. | World J Hepatol | 2025 | https://conductscience.org/library/papers/41024879 | PubMed |
| 39944245 | Novel online calculator to predict reduced risk of early recurrence from adjuvant transarterial chemoembolisation for patients with hepatocellular carcinoma. | eGastroenterology | 2023 | https://conductscience.org/library/papers/39944245 | PubMed |
| 39648422 | A Review on Hepatoprotective Effect of Chrysin: Preclinical Implications and Molecular Cascades Came into Focus. | Curr Diabetes Rev | 2026 | https://conductscience.org/library/papers/39648422 | PubMed |
| 39290260 | Development and validation of a nomogram for predicting microvascular invasion and evaluating the efficacy of postoperative adjuvant transarterial chemoembolization. | Heliyon | 2024 | https://conductscience.org/library/papers/39290260 | PubMed |
| 38322198 | Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives. | Hepatobiliary Surg Nutr | 2024 | https://conductscience.org/library/papers/38322198 | PubMed |
| 38164269 | Survival effects of postoperative adjuvant TACE in early-HCC patients with microvascular invasion: A multicenter propensity score matching. | J Cancer | 2024 | https://conductscience.org/library/papers/38164269 | PubMed |
| 38107186 | 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations. | J Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/38107186 | PubMed |
| 37864725 | Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. | Hepatol Int | 2024 | https://conductscience.org/library/papers/37864725 | PubMed |
| 37696656 | Mouse Models of Metastasis and Dormancy. | Cold Spring Harb Perspect Med | 2024 | https://conductscience.org/library/papers/37696656 | PubMed |
| 37287040 | Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study. | Radiat Oncol | 2023 | https://conductscience.org/library/papers/37287040 | PubMed |
| 37070467 | Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization. | Ann Med | 2023 | https://conductscience.org/library/papers/37070467 | PubMed |
| 37052853 | DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis. | Cell Oncol (Dordr) | 2023 | https://conductscience.org/library/papers/37052853 | PubMed |
| 36525610 | Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36525610 | PubMed |
| 36050540 | Vessels that encapsulate tumor clusters (VETC) pattern predicts the efficacy of adjuvant TACE in hepatocellular carcinoma. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/36050540 | PubMed |
| 35686094 | The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. | Front Oncol | 2022 | https://conductscience.org/library/papers/35686094 | PubMed |
| 35070063 | Neoadjuvant treatment strategies for hepatocellular carcinoma. | World J Gastrointest Surg | 2021 | https://conductscience.org/library/papers/35070063 | PubMed |
| 34641921 | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34641921 | PubMed |
| 34097307 | Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | Hepatology | 2021 | https://conductscience.org/library/papers/34097307 | PubMed |
| 33854587 | A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma. | J Cancer | 2021 | https://conductscience.org/library/papers/33854587 | PubMed |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL185 | ChEMBL |
| LEVOLEUCOVORIN | CHEMBL1908841 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1908841 | ChEMBL |
| OXALIPLATIN | CHEMBL414804 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL414804 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12372721
GET https://conductscience.org/api/papers/v1/12372721/cited_by?page=2